Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9828397 | 0.85 | FFAR1 (0.64) | PDE10AGPBAR1FFAR1AKR1B1CYSLTR1 | |
| SCHEMBL28002107 | 0.84 | DHFR (0.58) | MEN1KMT2ASMN1; SMN2CYP1A2PDE10A | |
| SCHEMBL11589528 | 0.83 | PTGS2 (0.55) | CYP1A2MAPK1ALDH1A1KDM4ELMNA | |
| SCHEMBL1695565 | 0.82 | AKT1 (0.51) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL25435433 | 0.80 | GPBAR1 (0.56) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL9828722 | 0.78 | ALOX5 (0.59) | PDE10AGPBAR1FFAR1AKR1B1CYSLTR1 | |
| SCHEMBL16065424 | 0.76 | PPARG (0.59) | CYP1A2ALDH1A1KDM4ELMNAHPGD | |
| SCHEMBL9026288 | 0.76 | GPBAR1 (0.69) | PDE10AGPBAR1FFAR1AKR1B1CYSLTR1 | |
| SCHEMBL10980763 | 0.76 | CYP1A2 (0.53) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL2913941 | 0.76 | PDE10A (0.61) | CYP1A2PDE10ACYSLTR1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815788-B2 | Anti-angiogenic compounds | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2017-11-14 | — | — | US | disclosed |
| US-9815788-B2 | Anti-angiogenic compounds | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2017-11-14 | — | — | US | disclosed |
| EP-3147280-A1 | ANTI-ANGIOGENIC COMPOUND | University College Dublin, National University of Ireland, Dublin (IE) | 2017-03-29 | — | — | EP | disclosed |
| US-20170050930-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-02-23 | — | — | US | disclosed |
| US-20170050930-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-02-23 | — | — | US | disclosed |
| EP-2877454-B1 | ANTI-ANGIOGENIC 2-STYRYL-QUINOLINE COMPOUNDS | UNIV DUBLIN (IE) | 2016-11-02 | — | — | EP | disclosed |
| US-9388138-B2 | Anti-angiogenic compounds | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-07-12 | — | — | US | disclosed |
| US-9388138-B2 | Anti-angiogenic compounds | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-07-12 | — | — | US | disclosed |
| US-20150218100-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218100-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050930-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, VHL | MEN1 4178/4885KMT2A 3493/4885NPC1 2305/4885 |
| US-20150218100-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, VHL | MEN1 4178/4885KMT2A 3493/4885NPC1 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.